The FDA has approved an injectable formulation of Leqembi, developed by Eisai and Biogen, facilitating weekly maintenance dosing that can be administered in patients' homes. This approval marks a significant step toward decentralized Alzheimer's disease treatment, improving patient convenience and potentially adherence. Alongside, several rare disease drugs and refined COVID-19 vaccine approvals signify ongoing regulatory activity in neurology and infectious diseases.